| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,630,000 |
| Market
Cap: |
13.95(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$129.52 - $265 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 664 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
100,397 |
1,200,397 |
5,371,251 |
5,588,274 |
| Total Sell Value |
$15,909,372 |
$214,459,372 |
$1,041,558,017 |
$1,085,894,829 |
| Total People Sold |
2 |
3 |
8 |
9 |
| Total Sell Transactions |
6 |
7 |
21 |
54 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wu Xiaobin |
President, COO & GM China |
• – – |
2022-06-06 |
4 |
S |
$141.99 |
$484,202 |
D/D |
(3,410) |
0 |
|
-13% |
|
| Wang Lai |
Global Head of R&D |
• – – |
2022-06-06 |
4 |
S |
$142.00 |
$93,718 |
D/D |
(660) |
0 |
|
-13% |
|
| Wang Lai |
Global Head of R&D |
• – – |
2022-05-17 |
4 |
OE |
$2.29 |
$4,025,737 |
D/D |
1,233,947 |
1,408,498 |
|
- |
|
| Wang Julia Aijun |
Chief Financial Officer |
• – – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
61,750 |
143,299 |
|
- |
|
| Wu Xiaobin |
President, COO & GM China |
• – – |
2021-12-15 |
4 |
A |
$30.13 |
$0 |
I/I |
0 |
0 |
|
- |
|
| Wang Lai |
Global Head of R&D |
• – – |
2021-12-15 |
4 |
A |
$30.13 |
$0 |
I/I |
0 |
0 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-12-14 |
4 |
AS |
$274.54 |
$417,211 |
D/D |
(1,500) |
0 |
|
-45% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-12-14 |
4 |
OE |
$119.96 |
$179,940 |
D/D |
1,500 |
1,500 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-12-01 |
4 |
S |
$357.32 |
$377,493 |
D/D |
(1,049) |
0 |
|
47% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-11-30 |
4 |
A |
$0.00 |
$0 |
D/D |
1,049 |
1,049 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-11-30 |
4 |
A |
$0.00 |
$0 |
D/D |
14,820 |
160,055 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-11-17 |
4 |
AS |
$376.16 |
$572,003 |
D/D |
(1,500) |
0 |
|
-50% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-11-17 |
4 |
OE |
$119.96 |
$179,940 |
D/D |
1,500 |
1,500 |
|
- |
|
| Wu Xiaobin |
President, COO & GM China |
• – – |
2021-11-09 |
4 |
AS |
$361.56 |
$855,038 |
D/D |
(2,334) |
0 |
|
-49% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2021-11-08 |
4 |
AS |
$343.10 |
$1,575,202 |
D/D |
(4,500) |
0 |
|
-47% |
|
| Wu Xiaobin |
President, COO & GM China |
• – – |
2021-11-08 |
4 |
AS |
$343.12 |
$2,727,625 |
D/D |
(7,666) |
0 |
|
-47% |
|
| Wang Lai |
Global Head of R&D |
• – – |
2021-10-31 |
4 |
GA |
$0.00 |
$0 |
I/I |
58,188 |
58,188 |
|
- |
|
| Wang Lai |
Global Head of R&D |
• – – |
2021-10-31 |
4 |
GD |
$0.00 |
$0 |
I/I |
58,188 |
0 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-10-19 |
4 |
AS |
$362.05 |
$559,163 |
D/D |
(1,500) |
0 |
|
-43% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-10-19 |
4 |
OE |
$119.96 |
$179,940 |
D/D |
1,500 |
1,500 |
|
- |
|
| Wang Lai |
Global Head of R&D |
• – – |
2021-09-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
58,188 |
174,551 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-09-20 |
4 |
AS |
$390.91 |
$2,387,774 |
D/D |
(6,000) |
0 |
|
-39% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2021-09-20 |
4 |
OE |
$119.96 |
$719,760 |
D/D |
6,000 |
6,000 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-09-15 |
4 |
AS |
$374.39 |
$9,864,173 |
D/D |
(26,158) |
0 |
|
-40% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2021-09-15 |
4 |
AS |
$29.31 |
$5,575,287 |
D/D |
(190,203) |
1,736,904 |
|
-40% |
|
527 Records found
|
|
Page 4 of 22 |
|
|
2.59 (1.65%) 
